CLEVELAND, Feb. 23, 2011 /PRNewswire/ — ViewRay™, Inc., a
privately held medical device company, has received U.S. FDA
marketing clearance for its radiotherapy treatment planning and
delivery software. The software is a critical component of the
company’s new radiation therapy system, which combines simultaneous
magnetic resonance imaging and radiotherapy delivery. Now in the
late stages of development, the integrated ViewRay system is
currently available only as a non–human use research system.
The company is working to secure FDA clearance for commercial
distribution of the system for clinical use.
“FDA clearance of our software represents a significant
milestone in the development of the ViewRay system,” said ViewRay
President and CEO Gregory M. Ayers, MD, PhD. “In the past year
ViewRay has achieved a string of notable successes, in funding and
partnerships as well as product development. It’s exciting to see
such progress with a product we believe will offer an advancement
in radiation therapy.” The ViewRay system is being designed to
provide continuous soft-tissue MRI during cancer treatment so that
clinicians can see precisely where the radiation is being
delivered.
ViewRay holds the exclusive worldwide license for its
combination of MRI and radiotherapy technologies. The company
recently secured $20 million in Series C financing intended to move
the ViewRay system through the final development and regulatory
processes, and toward the goal of commercialization and placement
in major medical centers.
About ViewRay
ViewRay, Inc., of Cleveland, Ohio, is a privately held medical
device company developing advanced radiation therapy technology for
the treatment of cancer. Using MRI-guided radiotherapy, the ViewRay
system is being designed to provide continuous soft-tissue imaging
during treatment. The system is being developed so that clinicians
will be able to see where the actual radiation dose is being
delivered
‘/>”/>